CA2525499C - Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees - Google Patents

Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees Download PDF

Info

Publication number: CA2525499C
Authority: CA; Canada
Prior art keywords: act; specific binding; cells; receptor; binding partner
Prior art date: 1994-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2525499A

Other languages

English (en)

Other versions

CA2525499A1 (fr

Inventor

Wayne Godfrey

Edgar George Engleman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Leland Stanford Junior University

Original Assignee

Leland Stanford Junior University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-10

Filing date

1995-02-06

Publication date

2011-01-25

1994-02-10 Priority claimed from US08/195,967 external-priority patent/US6242566B1/en

1995-02-06 Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University

1995-08-17 Publication of CA2525499A1 publication Critical patent/CA2525499A1/fr

2011-01-25 Application granted granted Critical

2011-01-25 Publication of CA2525499C publication Critical patent/CA2525499C/fr

2015-02-06 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000003446 ligand Substances 0.000 title claims abstract description 161
210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 62
210000004027 cell Anatomy 0.000 claims abstract description 197
230000009870 specific binding Effects 0.000 claims abstract description 129
238000009739 binding Methods 0.000 claims abstract description 115
230000027455 binding Effects 0.000 claims abstract description 112
238000000034 method Methods 0.000 claims abstract description 97
239000012634 fragment Substances 0.000 claims abstract description 81
241000282414 Homo sapiens Species 0.000 claims abstract description 49
150000007523 nucleic acids Chemical class 0.000 claims abstract description 27
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims abstract description 25
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
102000039446 nucleic acids Human genes 0.000 claims abstract description 18
108020004707 nucleic acids Proteins 0.000 claims abstract description 18
239000013604 expression vector Substances 0.000 claims abstract description 13
238000012544 monitoring process Methods 0.000 claims abstract description 7
102000005962 receptors Human genes 0.000 claims description 216
108020003175 receptors Proteins 0.000 claims description 216
101100161935 Caenorhabditis elegans act-4 gene Proteins 0.000 claims description 212
108090000765 processed proteins & peptides Proteins 0.000 claims description 168
229920001184 polypeptide Polymers 0.000 claims description 164
102000004196 processed proteins & peptides Human genes 0.000 claims description 164
108090000623 proteins and genes Proteins 0.000 claims description 81
150000001413 amino acids Chemical class 0.000 claims description 62
125000003275 alpha amino acid group Chemical group 0.000 claims description 60
102000004169 proteins and genes Human genes 0.000 claims description 50
210000003719 b-lymphocyte Anatomy 0.000 claims description 43
239000002773 nucleotide Substances 0.000 claims description 34
230000004913 activation Effects 0.000 claims description 33
125000003729 nucleotide group Chemical group 0.000 claims description 33
230000028993 immune response Effects 0.000 claims description 32
239000003795 chemical substances by application Substances 0.000 claims description 31
239000003153 chemical reaction reagent Substances 0.000 claims description 30
239000003814 drug Substances 0.000 claims description 25
239000012491 analyte Substances 0.000 claims description 20
238000012360 testing method Methods 0.000 claims description 17
108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
230000000295 complement effect Effects 0.000 claims description 16
238000012216 screening Methods 0.000 claims description 16
238000000338 in vitro Methods 0.000 claims description 14
230000003834 intracellular effect Effects 0.000 claims description 13
239000011230 binding agent Substances 0.000 claims description 12
210000004408 hybridoma Anatomy 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
208000023275 Autoimmune disease Diseases 0.000 claims description 11
108020001507 fusion proteins Proteins 0.000 claims description 11
208000015181 infectious disease Diseases 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 11
238000001514 detection method Methods 0.000 claims description 10
102000037865 fusion proteins Human genes 0.000 claims description 10
108700012359 toxins Proteins 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 9
206010052779 Transplant rejections Diseases 0.000 claims description 9
230000004054 inflammatory process Effects 0.000 claims description 9
239000003053 toxin Substances 0.000 claims description 9
231100000765 toxin Toxicity 0.000 claims description 9
238000001574 biopsy Methods 0.000 claims description 8
210000004899 c-terminal region Anatomy 0.000 claims description 8
230000004048 modification Effects 0.000 claims description 7
238000012986 modification Methods 0.000 claims description 7
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
230000000890 antigenic effect Effects 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
238000002405 diagnostic procedure Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
239000000463 material Substances 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
241000700605 Viruses Species 0.000 claims description 4
230000004968 inflammatory condition Effects 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
239000002955 immunomodulating agent Substances 0.000 claims description 3
239000012678 infectious agent Substances 0.000 claims description 3
239000002502 liposome Substances 0.000 claims description 3
230000007812 deficiency Effects 0.000 claims description 2
208000024908 graft versus host disease Diseases 0.000 claims description 2
230000002519 immonomodulatory effect Effects 0.000 claims description 2
238000000159 protein binding assay Methods 0.000 claims description 2
230000002285 radioactive effect Effects 0.000 claims description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
201000010099 disease Diseases 0.000 abstract description 13
210000000987 immune system Anatomy 0.000 abstract description 6
235000001014 amino acid Nutrition 0.000 description 61
229940024606 amino acid Drugs 0.000 description 59
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 50
235000018102 proteins Nutrition 0.000 description 44
101100110682 Lactococcus lactis subsp. lactis (strain IL1403) atpH gene Proteins 0.000 description 37
108091033319 polynucleotide Proteins 0.000 description 36
239000002157 polynucleotide Substances 0.000 description 36
102000040430 polynucleotide Human genes 0.000 description 36
239000000427 antigen Substances 0.000 description 34
108091007433 antigens Proteins 0.000 description 34
102000036639 antigens Human genes 0.000 description 34
239000002299 complementary DNA Substances 0.000 description 33
239000000523 sample Substances 0.000 description 31
108060003951 Immunoglobulin Proteins 0.000 description 29
102000018358 immunoglobulin Human genes 0.000 description 29
210000001519 tissue Anatomy 0.000 description 25
210000000265 leukocyte Anatomy 0.000 description 24
229940124597 therapeutic agent Drugs 0.000 description 22
238000010186 staining Methods 0.000 description 16
108020004414 DNA Proteins 0.000 description 15
230000003993 interaction Effects 0.000 description 15
230000000284 resting effect Effects 0.000 description 15
210000001616 monocyte Anatomy 0.000 description 14
241000894007 species Species 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
230000001413 cellular effect Effects 0.000 description 13
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 12
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 12
230000000694 effects Effects 0.000 description 12
239000013598 vector Substances 0.000 description 12
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 11
230000004044 response Effects 0.000 description 11
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 10
230000006870 function Effects 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
102000006395 Globulins Human genes 0.000 description 9
108010044091 Globulins Proteins 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
238000013459 approach Methods 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000004927 fusion Effects 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
108020004999 messenger RNA Proteins 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
241000894006 Bacteria Species 0.000 description 7
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 7
101710125418 Major capsid protein Proteins 0.000 description 7
108010076504 Protein Sorting Signals Proteins 0.000 description 7
102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 7
210000003714 granulocyte Anatomy 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
241001529936 Murinae Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
238000007792 addition Methods 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
239000003018 immunosuppressive agent Substances 0.000 description 6
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 6
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 6
230000002147 killing effect Effects 0.000 description 6
210000004698 lymphocyte Anatomy 0.000 description 6
230000002093 peripheral effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000013519 translation Methods 0.000 description 6
101150013553 CD40 gene Proteins 0.000 description 5
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 5
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
102000018697 Membrane Proteins Human genes 0.000 description 5
108010052285 Membrane Proteins Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
241000288906 Primates Species 0.000 description 5
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
239000000556 agonist Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
230000013595 glycosylation Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
229940072221 immunoglobulins Drugs 0.000 description 5
229940125721 immunosuppressive agent Drugs 0.000 description 5
230000002637 immunotoxin Effects 0.000 description 5
239000002596 immunotoxin Substances 0.000 description 5
231100000608 immunotoxin Toxicity 0.000 description 5
229940051026 immunotoxin Drugs 0.000 description 5
CVKBYFCJQSPBOI-UHFFFAOYSA-N methyl 3-[(4-methylphenyl)sulfonylamino]benzoate Chemical compound COC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC(C)=CC=2)=C1 CVKBYFCJQSPBOI-UHFFFAOYSA-N 0.000 description 5
238000004091 panning Methods 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
230000007017 scission Effects 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000000047 product Substances 0.000 description 4
229960000814 tetanus toxoid Drugs 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
-1 ~i-galactosidase Proteins 0.000 description 4
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
108010041397 CD4 Antigens Proteins 0.000 description 3
241000283707 Capra Species 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
101150064015 FAS gene Proteins 0.000 description 3
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000043131 MHC class II family Human genes 0.000 description 3
108091054438 MHC class II family Proteins 0.000 description 3
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108010004729 Phycoerythrin Proteins 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 3
230000006044 T cell activation Effects 0.000 description 3
108091036066 Three prime untranslated region Proteins 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000008484 agonism Effects 0.000 description 3
230000000961 alloantigen Effects 0.000 description 3
230000000735 allogeneic effect Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000003125 immunofluorescent labeling Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
235000015110 jellies Nutrition 0.000 description 3
239000008274 jelly Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000035772 mutation Effects 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
230000000242 pagocytic effect Effects 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
101710112752 Cytotoxin Proteins 0.000 description 2
238000009007 Diagnostic Kit Methods 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
208000036566 Erythroleukaemia Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
208000005599 HTLV-I Infections Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
239000006137 Luria-Bertani broth Substances 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
239000012163 TRI reagent Substances 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000002981 blocking agent Substances 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
239000002619 cytotoxin Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
125000001165 hydrophobic group Chemical group 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000010820 immunofluorescence microscopy Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000011532 immunohistochemical staining Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000013507 mapping Methods 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000014207 opsonization Effects 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
238000002823 phage display Methods 0.000 description 2
210000001539 phagocyte Anatomy 0.000 description 2
239000012071 phase Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000009822 protein phosphorylation Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
108020005065 3' Flanking Region Proteins 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
229940117976 5-hydroxylysine Drugs 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
101150028668 APO1 gene Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
0 CC1C*CCC1 Chemical compound CC1C*CCC1 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108010084313 CD58 Antigens Proteins 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
101710130444 CD70 antigen Proteins 0.000 description 1
108010032795 CD8 receptor Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
101100030140 Chlamydia pneumoniae pmp11 gene Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000699662 Cricetomys gambianus Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
241000283014 Dama Species 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
108020005199 Dehydrogenases Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000588921 Enterobacteriaceae Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
FUCOMWZKWIEKRK-UHFFFAOYSA-N IC1CCCCC1 Chemical compound IC1CCCCC1 FUCOMWZKWIEKRK-UHFFFAOYSA-N 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102100022339 Integrin alpha-L Human genes 0.000 description 1
102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
241000404883 Pisa Species 0.000 description 1
231100000742 Plant toxin Toxicity 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
241000700564 Rabbit fibroma virus Species 0.000 description 1
101100022872 Rattus norvegicus Ment gene Proteins 0.000 description 1
101000679843 Rattus norvegicus Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000607720 Serratia Species 0.000 description 1
241000219289 Silene Species 0.000 description 1
101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
206010072148 Stiff-Person syndrome Diseases 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101150009046 Tnfrsf1a gene Proteins 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
101710113414 Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 1
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
101100221226 Zea mays COAC2 gene Proteins 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
231100000659 animal toxin Toxicity 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000001494 anti-thymocyte effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000002089 crippling effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
201000010549 croup Diseases 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
JNSGIVNNHKGGRU-JYRVWZFOSA-N diethoxyphosphinothioyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound CCOP(=S)(OCC)OC(=O)C(=N/OC)\C1=CSC(N)=N1 JNSGIVNNHKGGRU-JYRVWZFOSA-N 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000006334 disulfide bridging Effects 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001983 electron spin resonance imaging Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000010437 gem Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000003712 glycosamine group Chemical group 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000012333 histopathological diagnosis Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
208000003669 immune deficiency disease Diseases 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000004031 neuronal differentiation Effects 0.000 description 1
230000006576 neuronal survival Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229940097886 phosphorus 32 Drugs 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000009738 saturating Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007447 staining method Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA2525499A 1994-02-10 1995-02-06 Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees Expired - Fee Related CA2525499C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/195,967 US6242566B1 (en)	1994-02-10	1994-02-10	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US08/195,967		1994-02-10
CA002183066A CA2183066A1 (fr)	1994-02-10	1995-02-06	Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002183066A Division CA2183066A1 (fr)	1994-02-10	1995-02-06	Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees

Publications (2)

Publication Number	Publication Date
CA2525499A1 CA2525499A1 (fr)	1995-08-17
CA2525499C true CA2525499C (fr)	2011-01-25

Family

ID=35767574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2525499A Expired - Fee Related CA2525499C (fr)	1994-02-10	1995-02-06	Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees

Country Status (1)

Country	Link
CA (1)	CA2525499C (fr)

1995
- 1995-02-06 CA CA2525499A patent/CA2525499C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2525499A1 (fr)	1995-08-17

Legal Events

Date	Code	Title	Description
2005-11-28	EEER	Examination request
2013-03-21	MKLA	Lapsed	Effective date: 20130206

Publication	Publication Date	Title
EP0741784B1 (fr)	2009-03-11	Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees
US7364733B2 (en)	2008-04-29	Antibody to receptor on the surface of activated T-cells: ACT-4
CA2525499C (fr)	2011-01-25	Ligand (act-4-l) se fixant sur un recepteur situe a la surface de cellules t cd4+ activees
AU784729B2 (en)	2006-06-01	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
HK1001462B (en)	2009-11-27	Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells
AU1843699A (en)	1999-05-06	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+T-cells
HK1001464B (en)	2007-04-13	Receptor on the surface of activated t-cells:acts-4